OFIX Earnings Prediction
The chart below shows how OFIX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, OFIX sees a +2.75% change in stock price 10 days leading up to the earnings, and a -0.43% change 10 days following the report. On the earnings day itself, the stock moves by -0.78%. This data can give you a slight idea of what to expect for the next quarter's release.
OFIX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
196.61M
6.85%
-1.01%
Gross Margin
66.38%
5.85%
1.08%
Operating Margin
-2.78%
-79.74%
-49.18%
Net Margin
-13.93%
-11.16%
-17.28%
EPS
-0.71
-7.79%
-19.32%
No Data Available
OFIX Earnings Analysis
Orthofix Medical Inc. Common Stock (DE) Corporation (OFIX.O) Earnings Conference Call
Positive
Third Quarter Net Sales Growth: The third quarter net sales reached $196.6 million, representing a year-over-year growth of 7%.
EBITDA Margin Expansion: Adjusted EBITDA was $19.2 million, with an adjusted EBITDA margin expansion of approximately $6 million or approximately 250 basis points.
Spine Fixation Revenue Surge: The U.S. spine fixation revenue grew 18%, significantly outpacing the market growth rate, driven by deeper penetration of existing accounts and expansion of the customer base.
Record 7D Navigation Agreements: The company achieved a record number of 7D flash navigation system agreements, matching the record for the highest number of 7D unit placements in any quarter to date.
Free Cash Flow Improvement: Free cash flow of $5.9 million was generated in the quarter, marking a significant improvement over the first half of this year.
Negative
International Business Decline: The international business declined 2% versus prior year.
Biosciences Market Performance: U.S. biosciences business grew below the overall market in the third quarter as we accelerated our distributor transformation, which had a disproportionate impact on our biosciences business.
Future Performance Expectations: We expect this performance to get back to an above-market pace as we continue to focus on new distributor partnerships, cross-selling initiatives and the launch of new products.
EBITDA Margin Expansion: The adjusted EBITDA margin expansion was driven by the capture of merger-related synergies and driving leverage on sales growth and represented a 45% growth on incremental revenue dollars.
Sales Guidance Update: We are maintaining our guidance for fully year net sales of $795 million to $800 million, representing implied growth of 6.6% to 7.2% year-over-year on a constant currency basis.
OFIX FAQs
How does OFIX typically perform around its earnings report dates?
Is Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
OFIX Earning Call Sentiment
Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
OFIX.O
-1.02%Positive
The earnings call summary indicates strong financial performance with a 7% YoY net sales growth and significant EBITDA margin expansion. The company raised its full-year sales and EBITDA guidance, signaling confidence in future performance. Despite competitive pressures and economic challenges, management anticipates positive free cash flow and sustained growth. The Q&A section reflects management's confidence in their strategic initiatives and market position. Although there are risks, the overall sentiment is positive, suggesting a likely stock price increase in the short term.